Argenx (ARGX) announced Sandrine Piret-Gerard has been appointed chief commercialization officer. Sandrine brings extensive commercial and medical affairs experience, most recently leading the U.S. commercial organization at Gilead (GILD) across virology and oncology.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $1,030 from $950 at Truist
- Argenx price target raised to $1,160 from $1,110 at Morgan Stanley
- Argenx price target lowered to $1,091 from $1,124 at Citi
- Argenx price target raised to EUR 880 from EUR 850 at Barclays
- Immunovant upgraded to Outperform at Wolfe on improving Graves’ perception